) the macrophage electrophoretic mobility (MEM) assay has generated controversy because of the problems of establishing the assay in other laboratories. The subject has been reviewed (Moore & Lajtha, 1977) and been the major subject of 2 recent symposia (Muller, 1978; Preece & Sabolovic, 1979) . The consensus from these appraisals is that the basic observations are essentially correct and repeatable in favourable circumstances.
The justification for regarding the MEM assay as a measure of an immune response has been examined (Dickinson, 1979) and rests on the necessity for the presence of lymphocytes; the lymphokine-like mechanisms of the assay; the small fraction of peripheral-blood lymphocytes responding; the demonstration of antigen specificity in in vitro "sensitization" and in the pattern of reactivity to extracts of tumours of particular sites by cancer patients' lymphocytes; the specificity and time course of generation of the response in artificially immunized animals; and finally on some anecdotal evidence for the long-lived anamnestic nature of the response. Against this background it seems acceptable to refer to materials provoking a response in the MEM assay as antigens.
Two such antigens, readily extracted with acid from human tissues and crossreactive in the MEM test, have been previously noted (Caspary & Field, 1 971; Dickinson et al., 1974) . The suggested universal occurrence of one (variously termed the common tumotur-specific antigen, cancer basic protein, CaBP and cancer EF, and here referred to as the tumour antigen) in human malignant tissues was discussed by and is supported by all our subsequent investigations. The other, which appears to be present in all human tissues, is similarly referred to here as normal tissue antigen. These two antigens are detected by their activity in the MEM test when lymphocytes from patients with solid malignant tumours are used as responding cells, and are qualitatively distinguished by the different plateau values of macrophage slowing which they give (Carnegie et al., 1973) .
Some properties of these two antigens have been noted previously. Thus the tumour antigen appears to be restricted in vivo to malignant neoplasias ; the 2 antigens show similarities in terms of proteolipid nature, basicity, localization on the external surface of the plasma membrane, and molecular size (-17,000 daltons) (Dickinson et al., 1974; Dickinson et al., 1972) . The cross-reactivity of the two antigens has been investigated using immunosorbent techniques (McDermott et al., 1974) .
Some of the properties previously described have depended on the tacit assumption that each antigen is a simple protein. The experiments presented here attempt to justify this assumption and also represent the start of an attack on the problem of defining the primary structures responsible for antigenic activity.
MATERIALS AND METHODS
Whole tumour cells.-HeLa, HeLa-S3, Hep-2 and FL cells were grown in monolayer cultures by standard techniques, except that the final harvest was effected, as previously, with buffered versene alone (Dickinson et al., 1972) . Leucocytes obtained during therapeutic leucopheresis from 3 patients with chronic lymphocytic leukaemia were received as saline-washed, packed and snap-frozen cells.
Acid extracts of solid tumours.-These were prepared separately as previously described from fresh surgical specimens (subsequently histologically assessed) of human carcinomas of stomach (3), colon (2), breast (5), vulva, cervix uteri, kidney and bronchus, from a carcinomatous mass in the omentum, and from a pool of various formalin-fixed tumours (Pool). Guinea-pig hepatoma was a kind gift from Dr M. Dale. Extracts were also prepared from the following normal human tissues obtained at surgery: spleen, breast (3), stomach, colon (2), kidney, term placenta and lung, from unfixed grossly normal liver obtained at necropsy and from normal guinea-pig liver.
The activities in the MEM test of a number of these extracts have been specifically noted in previous papers in this series; each extract was tested and shown to be active before further use.
Enzymes.-Trypsin. Four types of trypsin were used: (i) DIFCO trypsin 1: 250;  (ii) trypsin Type III (Sigma Chemical Co.); (iii) DCC-trypsin Type III (Sigma), in which chymotrypsin had been inhibited by treatment with the selective inhibitor diphenylcarbamyl chloride; (iv) Enzygel-trypsin (Boehringer, Mannheim) which was treated with 1-(4-tosylamido)-2-phenylethyl chloromethyl ketone (TPCK) to inactivate residual chymotrypsin (Carpenter, 1967) .
Pronase (British Drug Houses) and protease (Subtilisin BPN) Type VII, ox-chymotrypsin Type II, pepsin (1: 60,000) and papain 2 x recrystallized (all from Sigma) were used.
Papain was activated by incubation for 10 min at 37°C in a small volume of the appropriate buffer containing 1 mg sodium cyanide for each 2-5 mg of enzyme protein before addition to the material to be digested.
Assay of antigenic activity.-The macrophage electrophoretic mobility (MEM) assay was described previously . Lymphocytes from patients bearing solid malignant tumours which were, pro tem., untreated, were used exclusively. Results are expressed as macrophage slowing relative to the slowing given by a reference antigen tested at the same time against the same lymphocytes and macrophages, and taken arbitrarily as 100. Details of reference antigens are given by Dickinson et al. (1974) .
Chromatography. ranging from 80 to 0-05 mg papain/109 cells. The digests were clarified by centrifugation at 18,000 g max., and the supernates fractionated as described below.
Enzymic digestion of acid extracts
Trypsin.-The effect of crude trypsin on the antigenic activity of whole cells described above suggested that, since inactivation of material in the supernate was a good deal slower than the rate of removal from the cell surface, the inactivation might be due to chymotryptic or other proteolytic impurities in the trypsin. An acid extract of a tumour (1 mg) was therefore digested with a commercial preparation of chymotrypsin-inhibited trypsin, i.e. ug) in 200 -lI 01M ammonium bicarbonate at 37°C for 2 h. The digest was fractionated on G-50 and the low-mol.-wt material tested. The same acid extract (1 mg) was also digested for 7 h at 37°C in 01M ammonium bicarbonate (2 ml) with 50 (BAE) units of an Enzygeltrypsin preparation which had been treated with TPCK to inactivate chymotrypsin. The simple digest supernate was tested; digestion was demonstrated by paper chromatography, and the mobilities of the active materials determined.
The stability of normal tissue antigen to non-chymotrypsin-inhibited trypsin was also investigated. The crude acid extract and the active fraction from G-200 of normal liver were digested with trypsin Type III and DCC-trypsin, respectively, and the low-mol.-wt fractions from G-50 tested for activity.
Papain.-An acid extract of a tumour was digested at 37°C with papain (4 mg extract/ mg papain) in tris-HCl buffer (0-2M) at pH 8.0, 7 0 and 6-0, and in sodium acetate (0.2M) adjusted to pH 5 0 and 4-0 with acetic acid. The digests were fractionated on G-50 and G-15 and tested for activity. Further tumour extracts were digested at 20 to 260 mg extract/mg papain, the digests fractionated as described below, and the fractions tested for activity. Acid extracts of normal tissues were also digested at pH 4-0 with papain (12-160 mg substrate/mg papain) and the fractionated digests tested for activity.
Other proteinases.-Extracts of normal and tumour tissue were digested with (i) chymotrypsin in 01M ammonium acetate (pH 8.8) containing 5 mm Ca++; (ii) pepsin in 01M HCI, or at higher pepsin: substrate ratios in 0-5M formic acid; (iii) subtilisin or pronase in 01M ammonium bicarbonate. The low-mol.-wt materials from G-50 were tested for activity, or in the case of pepsin the frozen dried digests were tested directly. Purification of active papain fragments Papain digests, prepared as noted above, were clarified by centrifugation at 18,000 g for 20 min and the supernates fractionated by gel filtration on G-50 in O-O1M ammonia. The active fraction was concentrated and further fractionated on G-15 or G-10 in the same solvent and the active fraction lyophilized. 
RESULTS
The results of the MEM assay with the reference antigens and lymphocytes from patients with malignancy used in these investigations were analysed previously (Dickinson et al., 1974) .
It should be emphasized that in this present context antigen or antigenic activity implies no more than the ability to release from the lymphocytes of known cancer bearers a factor which causes a reduction of electrophoretic mobility of particular (Shenton, Hughes & Field, 1973) oil-induced peritoneal macrophages of guinea-pigs. This factor is rarely released bv the lymphocytes of young, apparently healthy individuals. The interpretation of the data to be presented is dependent on the nature of the dose-19 response relationship of the MEM assay (Carnegie et al., 1973 (Dickinson et al., 1972) .
The inactivation of the tumour antigen activity in the supernatants, which appears to take place more slowly than the release into solution, is probably due to the presence of chymotrypsin in the DIFCO trypsin. Further evidence to this effect is given in the Table, which shows that whilst chymotrypsin readily inactivates the tumour antigen, a fully chymotrypsininhibited trypsin preparation (Enzygel-TPCK trypsin) does not, whereas a commercial preparation (DCC-trypsin) is less effectively inhibited, leaving normal tissue antigen still active in the digest.
After digestion of Hep-2 cells with papain at pH 4-0 for 1.5, 3 0 and 18 h, the cell residue, tested at 106 cells/test, gave relative slowings of 90, 71 and 42 respectively. The appropriate fraction of each supernatant was found to contain activity in the tumour-antigen range. It appears that with an enzyme-substrate ratio of 1 mg papain/108 cells, 3h incubation is adequate to bring all the tumour-specific activity into solution in low-mol.-wt form. Partial purification of the active papain fragment Clarified papain (pH 4.0) digests of whole cells, or acid extracts of cells or malignant or normal tissues, were fractionated by chromatography successively on G-50, G-15 and cellulose (either as packed columns or as paper). Separations are illustrated in Fig. 2a, 2b and 3 . The only active fraction from G-50 (Pap 3) would contain peptide material < 6000 daltons, and that from G-15 (Pap 3A) would contain peptide material of > 2000 separation step is extremely effective in increasing the specific activity of the active fragment, since the weights of material recovered from the active region of the chromatograms were unmeasurably small. The separation procedure was successfully scaled up to column size, and a representative separation is illustrated in Fig. 3 
DISCUSSION
Two antigenic activities which appear to be associated with all malignant tissues (tumour antigen) and with normal tissue in vivo (normal tissue antigen) have previously been described. The susceptibilities of these active materials to digestion (i.e. destruction of activity and/or reduction in molecular size) with a variety of proteolytic enzymes are described here, and suggest that the activities are associated with short peptide sequences within the protein molecules, as was postulated earlier by analogy with the cross-reacting antigenic determinant of myelin basic protein MBP (Caspary & Field, 1971; McDermott et al., 1974) . The material may, of course, be a glycopeptide, though evidence The ready liberation of (particularly tumour-type) activity by proteolytic digestion from viable (dye-excluding) cells emphasizes the finding that the antigenic activity is a cell-surface phenomenon (Dickinson et al., 1972) .
Tryptic and papain digestions yield small, active fragments of the tumour antigen. The papain fragment is favoured for further study directed to sequence analysis. Whereas the active peptide from tryptic digestion, with its low mobility, is still mixed with a large amount of inactive peptide material, the extraordinarily high mobility of the papain fragment on paper in BAW takes it well away from the vast excess of inactive material in the papain digest; thus the purification problem is vastly simplified. This is especially important in view of the minute amount of material which appears to be associated with the activity.
The observation that digestion of extracts of tumours with non-chymotrypsininhibited trypsin yielded material with normal tissue antigen-type activity was originally confusing, but is now clearly seen to be due to (i) the presence (not surprising in view of the rough dissections of tumours generally carried out) of normal tissue antigen in tumour extracts, as evidenced by the chromatographic separation of the two activities after TPCKtryptic digestion, and (ii) the relative stability of the normal tissue activity to chymotryptic digestion, as evidenced by the finding of this activity on tumour cells and in supernates after digestion with crude trypsin. The latter finding strongly suggests that normal tissue antigen is also present on the surface of tumour cells.
The failure of active materials to react with ninhydrin on paper, even though they are at least partly peptidic in nature, and the very small amount of material recovered in active fractions, even though activity appears to be recovered in high yield (manuscript in preparation) suggest that the tumour and normal tissue antigens constitute only a minute proportion of the materials extracted with acid. The uniform behaviour of the tumour-antigen papain fragment suggests that the antigens from individual tumours may have identical structures, and justifies the pooling of materials to obtain sufficient for structural studies.
The chromatographic separation of tryptic peptides with tumour-type and normal tissue-type activity supports the qualitative distinction between these cross-reacting activities. The distinction was originally made solely on the basis of the quantitatively different plateau showing effects caused, presumably, by release of qualitatively different lymphokines from the same sensitized lymphocytes. This last point may well have implications beyond the field of tumour immunology.
